# Cholinergic Enhancement of Theta

> **NCT07228338** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Epilepsy
- Seizures
- Cognitive Impairment, Mild
- Memory Disorder
- Memory Loss

## Interventions

- **DRUG:** COBENFY KarXT (50/20 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07228338
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2031-10
- **Final completion:** 2031-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228338, "Cholinergic Enhancement of Theta". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07228338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*